Effectiveness of very low doses of immunotherapy in advanced renal cell cancer

This publication has 16 references indexed in Scilit:

• Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-α
  European Journal Of Cancer, 1994
• A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-α in the treatment of advanced renal cell carcinoma or melanoma
  European Journal Of Cancer, 1994
• Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications.
  1993
• A Randomized Study of Low-Dose Interleukin-2 Subcutaneous Immunotherapy versus Interleukin-2 plus Interferon-Alpha as First Line Therapy for Metastatic Renal Cell Carcinoma
  Tumori Journal, 1993
• A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects
  British Journal of Cancer, 1993
• CLINICAL AND IMMUNOLOGICAL EFFECTS OF RECOMBINANT INTERLEUKIN-2 GIVEN BY REPETITIVE WEEKLY CYCLES TO PATIENTS WITH CANCER
  1988
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
  New England Journal of Medicine, 1987
• Reporting results of cancer treatment
  Cancer, 1981
• Prognosis in renal carcinoma
  Cancer, 1970